Exelixis has submitted an investigational new drug application
(IND) to the US Food and Drug Administration (FDA) for XL820, a
novel small molecule anticancer compound that inhibits receptor
tyrosine kinases (RTKs) implicated in tumour...
A new therapeutic technique based on a small molecule working in
tandem with a larger protein has been shown to block accumulation
of the brain-clogging amyloid protein seen in Alzheimer's disease,
raising the possibility of...